Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bill Proposes Offering Exclusivity For Novel Drug Co-Development

Executive Summary

Bill proposes six months’ extra marketing exclusivity to spur development of combinations of investigational drugs for serious diseases. Setting aside prospects for passage in an election season, the question is whether that will be enough to get pharma to buy into a risky development space and pioneer a new business model.

Advertisement

Related Content

FDA Antibiotic Task Force Developing Standards To Help Products GAIN Traction
View From ICAAC: How Higher Prices Can Help Save Antibiotic R&D
Bristol/Roche Finally Start Combination Melanoma Trial
Beyond The Guidance: The Business Of Co-Development Combinations
Drug Developers Ask For Flexible Combinations In Co-Development Regulation
FDA Issues Co-Development Guidance, But Only For Products Treating "Serious" Diseases
In A First, Merck And AstraZeneca Team Up For Oncology Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel